CompletedNot Applicable

Effect of Chickpea Protein Hydrolysate Supplementation on Muscle Damage and Inflammatory Plasma Markers During a Football Tournament: A Randomized, Placebo-Controlled Crossover Trial

Spain51 participantsStarted 2022-02-14

Plain-language summary

This randomized, placebo-controlled crossover study evaluated the safety and potential beneficial effects of a beverage containing chickpea protein hydrolysate in football players. Participants received the chickpea protein hydrolysate beverage and a matched protein-containing placebo beverage during two four-week intervention periods separated by a two-week washout period. The study assessed biochemical safety parameters, antioxidant status, inflammatory biomarkers, lipid profile, lipid peroxidation, muscle damage markers, dietary intake, and body composition.

Who can participate

Age range

16 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Football player belonging to one of the participating professional, semiprofessional, or amateur football teams. * Regular participation in the team's training sessions and matches. * Considered healthy based on medical history, biochemical assessment, body composition, lifestyle assessment, and dietary evaluation. * Ability and willingness to comply with the study procedures and beverage consumption schedule. * Provision of written informed consent. Exclusion Criteria: * Presence of chronic disease, including cardiovascular disease, diabetes, cancer, or metabolic syndrome. * Overweight, renal impairment, or hepatic impairment. * Abnormal biochemical test results considered clinically relevant by the research team. * Known allergy to chickpea. * Use of medication or nutritional supplements during the four weeks preceding enrollment. * Current smoking. * Participation in another similar study during the previous three months. * Completion of less than 75% of the scheduled training sessions or matches during the study. * Failure to consume 100% of the assigned study beverage. * Any circumstance that, in the opinion of the research team, could impair participation or compliance with the study procedures.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Participants With Adverse Events During Each Intervention Period

Timeframe: During the first 4-week intervention period and the second 4-week intervention period, up to Week 10

Change in Circulating Interleukin-6 Concentration

Timeframe: Baseline and Weeks 4, 6, 10, and 12; the primary crossover comparison used the phase-specific changes from Weeks 0 to 4 and Weeks 6 to 10.

Change in Circulating Interleukin-8 Concentration

Timeframe: Baseline and Weeks 4, 6, 10, and 12; the primary crossover comparison used the phase-specific changes from Weeks 0 to 4 and Weeks 6 to 10.

Change in C-Reactive Protein Concentration

Timeframe: Baseline and Weeks 4, 6, 10, and 12; the primary crossover comparison used the phase-specific changes from Weeks 0 to 4 and Weeks 6 to 10.

Change in Creatine Kinase Activity

Timeframe: Phase-specific baseline and end of each 4-week intervention period, corresponding to Weeks 0, 4, 6, and 10.

Change in Lactate Dehydrogenase Activity

Timeframe: Phase-specific baseline and end of each 4-week intervention period, corresponding to Weeks 0, 4, 6, and 10.

Trial details

NCT IDNCT07765719

SponsorInstituto de la Grasa

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2022-05-17

View on ClinicalTrials.gov More Post-Exercise Recovery trials

Plain-language summary

Who can participate

Age range

16 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Number of Participants With Adverse Events During Each Intervention Period

Timeframe: During the first 4-week intervention period and the second 4-week intervention period, up to Week 10

Change in Circulating Interleukin-6 Concentration

Timeframe: Baseline and Weeks 4, 6, 10, and 12; the primary crossover comparison used the phase-specific changes from Weeks 0 to 4 and Weeks 6 to 10.

Change in Circulating Interleukin-8 Concentration

Timeframe: Baseline and Weeks 4, 6, 10, and 12; the primary crossover comparison used the phase-specific changes from Weeks 0 to 4 and Weeks 6 to 10.

Change in C-Reactive Protein Concentration

Timeframe: Baseline and Weeks 4, 6, 10, and 12; the primary crossover comparison used the phase-specific changes from Weeks 0 to 4 and Weeks 6 to 10.

Change in Creatine Kinase Activity

Timeframe: Phase-specific baseline and end of each 4-week intervention period, corresponding to Weeks 0, 4, 6, and 10.

Change in Lactate Dehydrogenase Activity

Timeframe: Phase-specific baseline and end of each 4-week intervention period, corresponding to Weeks 0, 4, 6, and 10.